-
Mashup Score: 16
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Hepatocellular carcinoma (HCC) relationship with hypertension is a complicated phenomenon, mainly depending on the causes of the primary liver disease and the potential for drug interactions between …
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Overall response rates and progression-free survival determined by radiographic assessment every 8 weeks are reliable intermediate end points for patients with unresectable hepatocellular carcinoma u…
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Grants Marketing Authorization to Edison Histotrispy System for Treatment of Liver Tumors - The ASCO Post - 6 month(s) ago
On October 9, HistoSonics, the manufacturer of the Edison System and novel histotripsy therapy platforms, announced the marketing authorization of its platform via the U.S. Food and Drug Administration’s (FDA) De Novo Classification Request process, a rigorous premarket review pathway for medical devices with no existing predicate. The Edison System is indicated for the noninvasive destruction of liver tumors, including unresectable liver tumors, using a nonthermal, mechanical process of focused ultrasound
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - Hepatobiliary - Could Neuroprotective Protein Play a Role in Progression of Liver Cancer? - 6 month(s) ago
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The HER2-targeting bispecific antibody zanidatamab generated rapid and durable responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer previously treated with gemcitabine, investigators from the global phase IIb HERIZON-BTC-01 study reported at the 2023 ASCO Annual Meeting. 1 The findings were simultaneously published in The Lancet Oncology. 2 HER2 is overexpressed or amplified in a subset of biliary tract cancer, and zanidatamab simultaneously targets
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Tucatinib/Trastuzumab for Previously Treated Patients With HER2-Positive Metastatic Biliary Tract Cancer - The ASCO Post - 6 month(s) ago
As reported in the Journal of Clinical Oncology by Nakamura et al, findings in a cohort of the phase II SGNTUC-019 basket study showed that tucatinib plus trastuzumab was active in previously treated patients with HER2-positive metastatic biliary tract cancer who had not received prior HER2-targeted therapy. The basket trial is evaluating tucatinib/trastuzumab in patients with HER2-altered solid tumors. In the international trial, 30 patients with previously treated HER2-overexpressing or -amplified
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - Hepatobiliary - Prognostic and Therapeutic Potential of CD73 Expression in Colorectal Cancer Liver Metastasis - 6 month(s) ago
By continuing to browse this site you permit us and our par tners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Cabozantinib Is Safe and Tolerable in Sorafenib-Intolerant HCC - 7 month(s) ago
The phase 2 ACTION trial, which evaluated the safety of second-line cabozantinib in patients with hepatocellular carcinoma who were intolerant to first-line sorafenib or who received agents other than sorafenib in the first line, did not meet its safety futility criteria, allowing the trial to continue.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - Hepatobiliary - Phase IIa Trial Focuses on Second-Line Trifluridine Plus Tipiracil and Irinotecan in Advanced Liver Cancer - 7 month(s) ago
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The incidence of biliary tract cancer in Ontario, Canada, is rising, highlighting the urgency of clinical trial enrollment to move the needle in cancer-specific outcomes. Read a new editorial by @ZhiVenFongMD et al. @oncoalert #HPBCSM https://t.co/OMl3waV36G